Our Product Platforms

As a result of over four years of product development, Integra has created two probiotic-based product platforms designed to prevent, or act as adjuvant treatment for clinically relevant oral health indications that affect 60-90% of the global population:

Gingivitis and Ear-Nose-Throat (ENT) Infections

Our first platform is an all-natural, probiotic lozenge that has been strategically formulated to fight many ENT infections such as pharyngitis, adenoiditis, and tonsilitis, in addition to gingivitis (inflammation of the gums). The unique, and synergistic combination of probiotics promote a healthier oral microbiome, prevent growth and colonization of ENT and plaque-forming bacteria, and beneficially modulate inflammation in the oral cavity.


Dental Caries (Cavities)

Our second platform is a probiotic-based product strategically formulated to combat dental caries through several distinct, and 
synergistic mechanisms: 

· Probiotic strains which specifically target and inhibit pathogenic bacteria directly responsible for caries development.

· A patented remineralization agent to reverse or prevent the progression of cavities.


Future Product Platforms

In addition to our current platforms, an extensive new probiotic-based, therapeutic-driven product development program pipeline is in place for additional untapped indications, such as women's health, geriatrics, urology, and cardiology.